SHM in castration resistant prostate cancer电子版

SHM in castration resistant prostate cancer电子版

ID:38371229

大小:284.63 KB

页数:5页

时间:2019-06-11

SHM in castration resistant prostate cancer电子版_第1页
SHM in castration resistant prostate cancer电子版_第2页
SHM in castration resistant prostate cancer电子版_第3页
SHM in castration resistant prostate cancer电子版_第4页
SHM in castration resistant prostate cancer电子版_第5页
资源描述:

《SHM in castration resistant prostate cancer电子版》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、SecondaryhormonalmanipulationincastrationresistantprostatecancerSohaibAl-Asaaed,MD,EricWinquist,MDLondonHealthSciencesCentreandWesternUniversity,London,Ontario,CanadaAL-ASAAEDS,WINQUISTE.Secondaryhormonaldiscussedwithpatientsandtheirpreferencesconsidered.manipulationincastrationres

2、istantprostatecancer.Inmenwithoutclinicalevidenceofmetastases,gonadalCanJUrol2014;21(Suppl1):37-41.androgensuppressionshouldbemaintainedandgenerallypatientsshouldbeobserved.ThereisnoclearevidenceIntroduction:CastrationresistantprostatecancerthatSHMsareofbenefitinthesepatients.Abira

3、terone(CRPC)isthesinglecommonpathwaytoprostateplusprednisoneisofprovenbenefitinmenwithCRPCcancerdeath.Formenwithsymptomaticmetastaticmetastaseswhoarewithoutsignificantsymptomspriordisease,docetaxelchemotherapyremainsastandardoftochemotherapy.Basedonemergingdata,enzalutamidecare.How

4、ever,bloodprostatic-specificantigen(PSA)maybeofsimilarbenefit.UseofotherSHMsshouldtestingallowstheidentificationofCRPCbeforeclinicalbebasedonpatientpreferenceandconsiderationofmetastasesorsymptomsoccur,providingalongdiagnosticpossibleadverseeffects;withtheexceptionoflowdoseleadtime

5、inmanypatients.Theuseofsecondaryprednisone,thereislittleevidenceofbenefitsupportinghormonalmanipulations(SHMs)inmennotcandidatestheiruse.Forpatientsacceptingtheseuncertainties,aforimmediatechemotherapyisreviewed.trialofnonsteroidalantiandrogenmaybeconsideredasanMaterialsandmethods:

6、PubMedwassearchedforadjuncttoobservation,followedbylowdosecorticosteroidrandomizedclinicaltrials,systematicreviewsorclinicalwithimmediateordelayedadditionofabiraterone(inmenpracticeguidelinesaddressingSHMsinCRPC.withmetastases)asareasonablenextstep.Results:Arecentsystematicreviewan

7、dpracticeguidelinewasidentified,andusedastheevidencebaseforthisreviewKeyWords:enzalutamide,hormone-dependent,alongwithreportsfromrandomizedtrialsoverthepastyear.prostaticneoplasms,castrationresistant,abiraterone,Conclusions:ThegoalsoftherapywithSHMsshouldbedrugtherapyIntroductionTh

8、ereisnocleartemporalrelati

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。